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Background: Trans-bronchial needle aspiration (TBNA) is a simple, safe technique that can
be performed without additional resources in any centre with a bronchoscopy service. It
provides rapid diagnostic information in malignant and benign conditions and staging
information in non-small cell lung cancer (NSCLC) and may avoid the delays, risks, in-
patient stay and financial implications associated with surgical exploration of the
mediastinum. Despite this, centres have been slow to adopt the technique. This may be
due to the lack of clarity about the clinical success of TBNA in everyday clinical practice
and the absence of a single valid measurement of clinical utility for TBNA against which to
audit.
Methods: We undertook a retrospective analysis of all TBNA carried out at Nottingham
City Hospital since the service began. ‘‘Success’’ was carefully and strictly defined. The
influences of various factors on the likelihood of a successful outcome were analysed.
Results: Fifty percent (71/142) of patients undergoing TBNA received an exact
histological diagnosis whilst in 72% (97/134) of patients in whom a final diagnosis was
made, TBNA results correctly predicted malignant versus benign conditions. We defined
the former, more stringent, outcome measure as ‘‘success—exact’’. This outcome was not
significantly affected by patient age or gender, lesion size or position, experience of the
bronchoscopist or number of aspiration attempts. Final diagnosis strongly influenced
‘‘success—exact’’ with NSCLC 6.5 times and small cell lung cancer 28.5 times more likely
to yield a diagnostic sample than benign conditions.
Conclusions: TBNA should be used as a standard first line invasive investigation for
diagnosis of mediastinal lymphadenopathy or submucosal endobronchial disease. The
stringent outcome defined in this study as ‘‘success—exact’’ is simple for clinicians and
patients to understand and would be a useful definition to standardise audit and future
research.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
nt.nhs.uk (D. Baldwin).
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Trans-bronchial needle aspiration (TBNA) is a simple, safe
technique which can provide useful diagnostic information
in both malignant and benign conditions, and can contribute
to the staging of non-small cell lung cancer (NSCLC).1–4 It is
used in the investigation of mediastinal and hilar lympha-
denopathy,5 exophytic endobronchial disease6,7 and sub-
mucosal disease or extrinsic compression8,9 of the proximal
airways. The use of TBNA potentially reduces the number of
higher risk surgical procedures such as mediastinoscopy and
the diagnostic delays and financial costs associated with
them.10 It is relatively easy to learn and can be established
in any hospital currently offering a bronchoscopy service
without major additional investment or equipment except
purchasing disposable needles. Despite this, there has been
evidence of a reluctance to offer a TBNA service and
consequent underutilisation of the technique both in the UK
and North America.11,12
Explanations for this include the paucity of clear data on
the clinical success and utility of TBNA from hospitals that
have not developed a service. There are also concerns about
the bronchoscopic expertise level of cytological support
required to set up a useful service.
The aim of this retrospective review of all TBNA
performed at Nottingham City Hospital (NCH) up to
September 2005 was to give an accurate representation of
the usefulness of this procedure in a clinical setting and to
measure the frequency of a successful outcome as defined
below. The effect of factors that might influence outcome
such as the position and size of the lesion, number of
aspiration attempts made, the experience of the bronch-
oscopist and the final diagnosis was examined.
As a result of the ethical difficulties in subjecting patients
to two investigative procedures and the consequent lack of a
gold standard comparison in individual cases, there is no
single valid measurement of clinical utility for this proce-
dure such as sensitivity and specificity that represents the
data effectively. We will discuss the relative merits and
inherent flaws in the way in which similar data has been
expressed in published literature and develop a working
definition of ‘‘clinical success’’.Methods
All bronchoscopies performed at NCH from the introduction
of TBNA in May 2000–September 2005 were reviewed. During
that period 142 procedures included TBNA.
All bronchoscopies were performed under light sedation
with local anaesthesia. A variety of fibreoptic bronchoscopes
were used including Olympus BF200 and 240 series. Samples
were taken with MAJ-66 Olympus (non-disposable introducer
with side slot), Olympus ‘‘Wang’’ disposable or Olympus
‘‘Wang’’ Histology needles. In the majority of cases a
cytology laboratory technician was present to make the
slides but on-site evaluation of the sample by a cytopathol-
ogist was not performed.
The service was started by DRB in May 2000 and these
data include all procedures performed. WSL was trained in
our unit and, in total, 98 of 142 procedures were performed
or supervised by these two consultant chest physicians.After adequate training by DRB and WSL during the period of
the study 44 procedures were performed by specialist
registrars and other consultants.
We defined clinical success in two ways. The first and
most rigorous was termed ‘‘success—exact’’ where the
technique was independently critical in determining the
diagnostic or staging information used to guide subsequent
management. The second was termed ‘‘success—predic-
tive’’ where TBNA correctly determined subsequent man-
agement, but where in some cases other biopsy techniques
were required to increase the confidence in the final
diagnosis. The majority of additional cases in this latter
group were non-malignant TBNA aspirates confirmed on
mediastinoscaopy.
Retrospective analyses of all of the medical records of the
patients, computerised radiology and pathology databases
and bronchoscopy reports were used to ascertain basic
demographic data, operator, number and site of samples
taken, the Computed tomography (CT) characteristics of the
lesion sampled, cytology from TBNA and the final diagnosis.
Most of these factors were discontinuous variables and
the statistical significance of their effect was determined by
w2-test. The sites from which samples were taken were
categorised into one of four positions for the purposes of
statistical analysis: tracheal, subcarinal, main bronchus and
segmental. CT size was grouped into four categories (p15,
16–25, 26–35 and 435mm in short axis diameter). The
influence of both on the outcome of TBNA were analysed
using w2-tests. The influence of age, a continuous variable,
was assessed with a paired t-test.
Statistical assessment of the impact of final diagnosis on
success was initially analysed using w2-tests on the diag-
nostic categories all benign conditions, NSCLC, small cell
lung cancer (SCLC), and other malignancies including
lymphoma. Logistic regression calculations were then used
to generate odds ratios.
This statistical analysis and subsequent logistic regression
was performed using Stata 7 software.
Results
Ninety eight (69%) of the 142 patients were male. The mean
age was 65.4 years. There were no significant complications.
One hundred and thirty-four (94%) of the 142 patients had a
final diagnosis of which 101 (75%) were malignant. Where
malignancy was not identified on TBNA, diagnosis was
achieved by CT-guided percutaneous biopsy, liver biopsy,
or surgical procedures. Benign diagnoses were either
confirmed by surgery, or by improvement or stability of
clinical and radiological parameters after prolonged follow
up or appropriate treatment. Those in whom a final
diagnosis was not made either declined or were unfit for
further invasive investigation.
Success—predictive
Cytology from TBNA correctly identified malignant or benign
disease within the lesions sampled in 97 (72%) of the 134
patients in whom a diagnosis was made. This number
includes 59 patients in whom TBNA positively identified
malignant disease, 5 where TBNA correctly determined node
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Table 2 The sensitivity and specificity of TBNA in
predicting malignancy and staging non-small cell lung
cancer. These values are included for comparison with
existing literature but should be interpreted with caution
as explained in the text.







Positive predictive 98.3 96.8
I. Le Jeune, D. Baldwin672negative disease subsequently confirmed at surgery, and 33
with non-malignant cytology in samples from those patients
later proven not to have a malignant condition. This latter
group comprises 7 definitive benign diagnoses made from
the TBNA sample including tuberculosis, sarcoidosis and a
bronchogenic cyst and 26 in whom cytological features,
while benign, did not lead to an exact diagnosis. There are
numerous reasons for the failure to make an exact benign
diagnosis: in 11 of these cases the samples did not contain
sufficient lymphoid tissue to guarantee that the aspirate was
successfully taken from the lymph node, in the rest the
cytopathologist was unable to differentiate between the
possible causes of granulomatous, inflammatory or fibrotic





Expressing these data in another way, TBNA provided an
exact diagnosis or accurate staging information in 71 (50%)
of the 142 patients who had the procedure. Of the 101 with
subsequently proven malignancy, TBNA provided either a
diagnosis or staging information in 64 (63%). Basic data are
summarised in Table 1.
With the reservations detailed in the subsequent discus-
sion, the ability of TBNA to diagnose malignant disease can
also be expressed in terms of sensitivity and specificity. For
the data presented here these values are sensitivity 62.1%,
specificity 97.4%, positive predictive value 98.3% and
negative predictive value 51.4% with an overall prevalence
of 70.9%. Looking specifically at the contribution of TBNA to
the staging of NSCLC in this study we calculated a sensitivity
of 61.2%, a specificity of 83.3% with a positive predictive
value of 96.8% and a negative predictive value of 20.8% on a
background prevalence of mediastinal lymph node involve-
ment of 89.1%. These results are summarised in Table 2.
We hypothesised that a range of factors including sex and
age of the patient, position and size of the lesion to be
biopsied, the number of aspiration attempts made, experi-
ence of the bronchoscopist in performing TBNAs might
influence the utility of TBNA. Their impact was statistically
analysed using the most stringent of the outcomes outlined
above where TBNA provided an exact histological diagnosis
(‘‘Success—exact’’). Data are presented in Table 3. w2
testing showed that none of these factors had a significant
impact on the outcome of TBNA.
Final diagnosis was the most important determinant of
the outcome of TBNA. Simple w2-tests on the impact of final
diagnosis grouped as NSCLC, SCLC, lymphoma, other





Malignant 101 64 (63.3%) 64 (63.3%)
Benign 33 33 (100%) 7 (21.2%)
Unknown 8
Total known 134 97 (72.3%)
Total 142 71 (50%)conditions on both ‘‘Success—predictive’’ and ‘‘Success—
exact’’ were highly significant (Po0.0001). As TBNA
correctly predicted all non-malignant diagnoses without
always providing useful diagnostic information this analysis
was also performed using ‘‘Success—exact’’ as the primary
outcome. Data are presented in Table 4. Clearly the
likelihood of achieving a diagnosis with TBNA is greater in
primary lung malignancies especially SCLC.
Discussion
Chest physicians frequently need to determine the signifi-
cance of mediastinal lymph node enlargement and sub-
mucosal or peribronchial disease in order to distinguish
benign and malignant processes and add essential staging
information for patients who turn out to have non-small cell
malignancies.
Non-invasive techniques such as CT scanning and positron
emission tomography (PET) scanning provide essential
radiological information based on size, characteristics and
metabolic activity of the lesion. Histological or cytological
samples are important, however, because of the suboptimal
sensitivity and specificity of both techniques and the need
for a definitve diagnosis before ruling out surgical treatment
in patients with malignancy.
The reference standard for invasive staging and diagnosis
is a surgical approach via mediastinoscopy, anterior med-
iastinotomy or thoracotomy depending on node station. This
has a sensitivity of 87% and specificity of 100% but requires
general anaesthesia and carries a risk of death in 0.2% and
morbidity in 1%.13 In addition there is an estimated cost of
$1700 for the procedure and $7500 when in-patient care
costs are added.14
In order to obviate the need for this, other, less invasive
techniques have been developed:1. Percutaneous, radiologically guided needle aspiration has
been used as a staging investigation but carries a
significant risk of bleeding from central vessel puncture
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Table 3 w2 analysis of the impact of various factors on the ability of TBNA to produce an exact diagnosis.
‘‘Success—Exact’’ Significance (w2)
Yes No P value
Sex
Male 44 (45%) 54 (55%) 0.07
Female 27 (61%) 17 (39%)
Age 65.5 (StDev 12.3) 65.3 (StDev 13.1) 0.93
Position
Tracheal 21 (52.5%) 19 (47.5%) 0.99
Subcarinal 31 (50%) 31 (50%)
Main bronchus 7 (54%) 6 (46%)
Segmental 12 (50%) 12 (50%)
Size (mm)
0–15 8 (50%) 8 (50%) 0.84
16–25 10 (50%) 10 (50%)
26–35 7 (47%) 8 (53%)
435 7 (64%) 4 (36%)
Attempts
1 or 2 17 (47%) 15 (53%) 0.15
3 or 4 33 (58%) 24 (42%)
5 or 6 7 (33%) 14 (67%)
Operator
DRB 33 (54%) 28 (46%) 0.53
WSL 19 (51%) 18 (49%)
Other 19 (43%) 25 (57%)
Table 4 The effect of final diagnosis on the success of TBNA expressed as the odds ratio of achieving an exact diagnosis in
non-small cell lung cancer, small cell lung cancer and other malignancies when compared to benign conditions.
Diagnosis Odds ratio 95% confidence intervals Significance P value
Benign 1 — —
NSCLC 6.5 2.4–17.7 o0.0001
SCLC 28.5 6.6–123.1 o0.0001
Other malignancies 1.6 0.4–5.7 ¼ 0.47
Measuring the success of TBNA 673and a 25–30% risk of pneumothorax in this circum-
stance.15 The risk of pneumothorax may be significantly
greater in patients with significant chronic obstructive
pulmonary disease (COPD).162. Transbronchial needle aspiration was developed in the
1980s by Wang and Terry.1 It is a method of sampling
performed via a flexible bronchoscope under conscious
sedation with a low consequent risk of complications.
The pooled risk of major complications including hae-
morrhage, pneumothorax requiring chest drainage and
pneumomediastinum, in a recent meta-analysis was
0.3%.17 Staging can be performed at initial diagnostic
bronchoscopy, providing the CT scan is available, redu-
cing risk to the patient and delay in subsequent
treatment. Important data from specialist centres
comparing the efficacy of the technique according the
endobronchial appearance of the lesion,18 size of needleused,19 number of aspirates Toloza and availability of
rapid on-site cytological evaluation (ROSE) 21 have
obscured the central message that this technique is a
safe and effective method of obtaining diagnostic or
staging information available to all those currently
offering bronchoscopy services.3. Endoscopic ultrasound-guided mediastinal lymph node
aspiration either via endobronchial (EBUS) or endooeso-
phageal (EEUS) approaches has been introduced more
recently. Defining a successful biopsy as one with
diagnostic cytology or the presence of lymphocytes to
indicate lymph node sampling Herth et al.22 reported a
success rate of 85% for endobronchial ultrasound guided
aspirations compared to 78% using the oesophageal
approach. A combination the two methods generated
successful biopsies in 94% and diagnoses in 94% of
patients. The authors concluded this was comparable to
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I. Le Jeune, D. Baldwin674mediastinoscopy. The major drawback of these techni-
ques is that they requires expensive equipment and a
skilled, experienced endoscopist with specific training,
they are therefore only available in a limited number of
centres.23Most of the literature comparing invasive approaches
comes from data generated in the staging of non-small cell
lung cancer. In a meta-analysis in 2003, Toloza et al.24
reviewed the evidence for all methods of invasive staging
and generated pooled sensitivity and specificity data for
each approach. For patients known to have non-small cell
lung cancer the sensitivity, specificity and number of
patients on whom the data were based were 81%, 100%,
n ¼ 5687 for mediastinoscopy; 91%, 100%, n ¼ 215 for
percutaneous radiologically guided biopsy; 76%, 96%, n ¼
910 for TBNA and 88%, 91%, n ¼ 215 for oesophageal
endoscopic ultrasound-guided aspiration.24 The authors
concluded that all methods were effective and that
selection would be influenced by availability, comorbidity
and the influence on procedure safety and the degree of
suspicion of metastatic disease.
Calculation of the sensitivity, specificity and positive and
negative predictive values is common practice among
publications addressing the usefulness of TBNA in staging
NSCLC. These figures are, however, dependent on certain
assumptions and thus should be interpreted with some
caution. Firstly patient safety and ethical considerations
make it impractical to confirm every positive result with a
gold standard investigation such as surgical sampling. While
it is reasonable to assume that a malignant diagnosis is a
true diagnosis in the vast majority of cases, there remains
the small possibility of sample contamination, for example
from an endobronchial tumour, producing ‘‘false positive’’
node status. This will be missed in most studies and lead to a
reduced false positive rate and thus over-estimation of the
specificity of the test. Further, proving that non-malignant
samples are true negatives with confidence is difficult
without a trial involving both TBNA and surgical sampling.
Most studies have elected to use surgical investigations
where clinically indicated and a period of clinical and
radiological follow up to exclude malignancy in those with
non-malignant cytology on TBNA. Cases where outcome
remains unclear have generally been excluded.
As an alternative, ‘‘success’’ of TBNA has been defined in
terms of percentage of diagnostic samples, avoidance of
surgical intervention, and, in those papers concerned with
staging, as the percentage of samples containing lymphoid
tissue and thus presumed to be taken from the appropriate
node. This outcome is also likely to overestimate the utility
of the procedure as successful aspiration of a lymph node
does not guarantee a useful diagnostic result. It will include
a number of false negative results, where cytological
interpretation of the sample is not possible based on the
tissue provided, and also false positive results. The variety
of outcome measures adopted makes it difficult to review
the literature and audit local performance.
For these reasons we have provided absolute numbers in
the results section. In the strictest definition of success of
the investigation where only samples that led to an exact
diagnosis and definitely, therefore, obviated the need forfurther investigation were counted (Success—exact), 50% of
all of the procedures were useful. Using the looser
definitions of success quoted in the majority of published
literature this figure could be made to appear significantly
higher. However, this outcome is simple to understand and
offers a clear measurement of the expected outcome for
chest physicians intending to set up a TBNA service. Given
the low inherent risk and complication rate of the procedure
and the fact that most of these patients undergo standard
bronchoscopy as part of their investigative work-up, this
additional rate of diagnosis is excellent and should en-
courage those debating the merits of this technique.
Alteration of the diagnostic pathway to ensure cross-
sectional imaging is available prior to bronchoscopy will
further increase the usefulness of this investigation.
Given the caveats outlined above the authors feel that
sensitivity and specificity are less helpful. Results from these
data do, however, highlight an important point. The
specificity of TBNA in staging NSCLC was reduced in this
dataset by a false positive result. This was found where a
subcarinal node, deemed malignant on TBNA, was found at
subsequent surgery to be benign. Clinicians involved in the
case made certain that the results were not falsely positive
as the question of contamination from an endobronchial
lesion had been raised by the cytologist. Where node
sampling is carried out for staging purposes in the presence
of an exophytic tumour mass aspirates should be interpreted
with caution.
In contrast to data from Hsu et al.25 we did not find
evidence to support a significant effect of experience of the
bronchoscopist on diagnostic outcome of TBNA. This finding
is in keeping with the reported experience from other
centres.26,27 In this series there was no evidence to support
a statistical effect on outcome of the number of aspiration
attempts made. In practice this depends on the initial
assessment of the quality of the samples obtained and the
tolerance of the patient to an extended procedure. Work by
Chin et al.20 would suggest that while 93% of diagnoses are
made within 4 aspiration attempts, up to 7 should be used
when possible. Neither the position or radiological size of
the lesion had an impact on outcome in this series. In a good
study from 2003, Sharafkhaneh et al.28 demonstrated no
significant impact of node station of TBNA yield but did
demonstrate that TBNA yield increased with increasing
lesion size28 supporting earlier data from Harrow et al.4
The failure of the data presented here to reflect that
common-sensical conclusion almost certainly relates to the
fact that the number of patients in whom lesion size was
accurately recorded in this study was small; in most cases
‘‘significant lymphadenopathy’’ or similar terms were
employed by the radiologists.
By far the most important determinant of diagnostic yield
was final diagnosis. These data attempt to quantify the
improved exact diagnostic rate in lung cancer, especially
small cell, over benign diagnoses. There are a number of
possible explanations for this marked effect but the effect
of structural differences between these lesions and reduced
cellular adherence in tumour cells on the quality of the
aspirates is the most plausible. These findings are reflected
by other series.4,28,29
In conclusion, previously published data have, in some
cases, been open to misinterpretation because of the
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adequacy as primary outcomes. This study reports the
overall clinical experience of a single large centre since the
introduction of TBNA and demonstrates a very favourable
true diagnostic rate in an unselected group of patients
further improved in those with lung cancer. In addition TBNA
is safe, simple, and can be incorporated into the standard
bronchoscopy undertaken on all of the patients presenting in
this way. It requires minimal additional funding and training
in centres equipped to perform bronchoscopies.
The authors feel that this study lends weight to the
argument that TBNA should be used as a standard first line
invasive investigation for diagnosis of mediastinal lympha-
denopathy or submucosal endobronchial disease and ex-
trinsic large airway compression. Early use of cross-sectional
imaging will allow this procedure to be the first diagnostic
and staging test in many cases. This would lead to an
avoidance of unnecessary surgical procedures which are
more invasive, expensive and induce some delay in diagnosis
in most centres. More sophisticated techniques involving
endoscopic ultrasound guidance may be appropriate second
line minimally invasive approaches in the few centres with
the necessary equipment and expertise.
The authors declare no competing interests. Work was
undertaken without sponsorship or outside funding. No
ethics approval was required for this study.
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